Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-07-03
2007-07-03
Tsang, Cecilia J. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S015800, C514S016700
Reexamination Certificate
active
10935593
ABSTRACT:
The present invention relates to a method of inhibiting fibrosis in a patient. The method comprises administering a therapeutically effective amount of a somatostatin, a somatostatin agonist or apharmaceutically acceptable salt thereof to said patent.
REFERENCES:
patent: 4853371 (1989-08-01), Coy et al.
patent: 4904642 (1990-02-01), Coy et al.
patent: 5480870 (1996-01-01), Kéri et al.
patent: 5753618 (1998-05-01), Cavanak et al.
patent: 6066616 (2000-05-01), Cavanak et al.
patent: 6268342 (2001-07-01), Culler et al.
patent: 6787521 (2004-09-01), Culler et al.
patent: 0 214 872 (1987-03-01), None
patent: 0 395 417 (1990-10-01), None
patent: 206 271 (1992-10-01), None
patent: 207 104 (1993-03-01), None
patent: WO 97/32604 (1997-09-01), None
Border, W. et al., “Natural inhibitor of transforming growth factor-B protects against scarring in experimental kidney disease,” Nature, 1992, 360:362-364.
Border, W. et al., “Transforming growth factor-B in glomerular injury,” Exp. Nephrol., 1994, 2:13-17.
Border, W. et al., “Transforming growth factor-B in tissue fibrosis,” New Eng. J. Med., 1994, 331:1286-1291.
Border, W. et al., “Targeting TGF-β for Treatment of Disease”, Nature Medicine, 1995, 1(10):1000-1001.
Flyvbjerg, A. et al., “Octreotide Administration in Diabetic Rats: Effects on Renal Hypertrophy and Urinary Albumin Excretion”, Kidney International, 1992, 41:805-812.
Karalis, K. et al., “Autocrine or paracrine inflammatory actions of corticotrophin-releasing hormone in vivo,” Science, 1991, 254:421-423.
Karalis, K. et al., “Somatostatin Analogues Suppress the Inflammatory Reaction In Vivo”, The Journal of Clinical Investigations, Inc., 1994, 93:2000-2006.
Karalis, K. et al., “Somatostatin May Participate in the Antiinflammatory Actions of Glucocorticoids”, Endocrinology, 1995, 136(9):4133-4138.
Lundergan, C. et al., “Inhibition of myointimal proliferation of the rat carotid artery by the peptides, angiopeptin and BIM 23034,” Atherosclerosis, 1989, 80:49-55.
Lyles, K. et al., “Peyronie's disease is associated with Paget's disease of bone,” J. Bone and Min. Res., 1997, 12:929-934.
Mizoi, T. et al., “Immunoelectron microscopic localization of transforming growth factor B1 and latent transforming growth factor B1 binding protein in human gastrointestinal carcinomas: qualitative difference between cancer cells and stromal cells,” Cancer Res., 1993, 53:183-190.
Najean, Y. et al., “Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases,” Leukemia and Lymphoma, 1996, 22:111-119.
Öberg, K. et al., “The Role of Interferons in The Management of Carcinoid Tumours”, British Journal of Haematology, 1991, 79:74-77.
Smiley, J. D., “Southwestern internal medicine conference: the many faces of scleroderma,” Am. J. of the Med. Sci., 1992, 304:319-333.
Steiner, E. et al., “Somatostatin: Progress in Segmental Pancreas Transplantation? An Experimental Study of Canine Duct-Occluded Grafts”, Transplantation Proceedings, 1984, vol. XVI:760-761.
Tahara, E., “Growth factors and oncogenes in human gastrointestinal carcinomas,” J. Cancer Res. Clin. Oncol., 1990, 116:121-131.
Tracy, T. et al., “Somatostatin Analogue (Octreotide) Inhibits Bile Duct Epithelial Cell Proliferation and Fibrosis After Extrahepatic Biliary Obstruction”, American Journal of Pathology, 1993, 143:1574-1578.
Tsukamoto, N. et al., “Octreotide treatment results in the inhibition of GH gene expression in the adenoma of the patients with acromegaly,” Endocrine J., 1994, 41:437-444.
Wahl, S. et al., “Cytokine regulation of schistosome-induced granuloma and fibrosis,” Kidney International, 1997, 51:1370-1375.
Buchler, M. et al., “Role of octreotide in the prevention of postoperative complications following pancreatic resection,” Am. J. Surgery, 163:125-131, 1992.
Logan, A. et al., “Enhanced expression of transforming growth factor B1 in the rat brain after localized cerebral injury,” Brain Res., 587:216-225, 1992.
Culler Michael D.
Kasprzyk Philip G.
Ball Pamela C.
Feeney Alan F.
Fish & Richardson
Societe de Conseils de Recherches et d'Applications Scientifique
Teller Roy
LandOfFree
Method of inhibiting fibrosis with a somatostatin agonist does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of inhibiting fibrosis with a somatostatin agonist, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of inhibiting fibrosis with a somatostatin agonist will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3756001